Fig. 1From: Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19Observed mean daily FLU-PRO Plus total score by study day. Based on data through Day 21, as shown in the end of study Week 24 database. FLU-PRO Plus inFLUenza Patient-Reported Outcome Plus, IV intravenousBack to article page